OVARIAN CANCER

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, reducing disease, the survival rate has improved. (The Fourth Annual Gene Therapy & Molecular Biology Conference, Rhodes, Greece)

American University of Iowa Dr. Richard Buller reported they received early treatment to strengthen the 36 patients with advanced ovarian cancer to the adenovirus vector into the peritoneal tumor suppressor gene p53 function of the combination of chemotherapy I / II clinical trials of the preliminary results. The results show that several gene therapy / chemotherapy combination therapy in patients with an average survival of 14.8. Nine people have survived 19.5 months, are still alive. The survival rate is higher than five separate gene therapy on the survival rate is also higher than the average with paclitaxel (Taxol) in the treatment of recurrent ovarian cancer new 15-month survival rate.

Tags: age, cancer, carboplatin, cause, chemotherapy, clinical, early, eat, gene, group, intraperitoneal, mutation, ovarian, p53, paclitaxel, patients, rate, reduce, survival, taxol, therapy, treatment, tumor

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Tags: anti, cancer, carboplatin, cases, cell, cells, chemotherapy, cisplatin, clinical, csa, days, dose, drug, drugs, eat, head, injection, intravenous, method, ovarian, paclitaxel, patients, positive, rate, reduce, response, study, surgery, survival, therapy, time, toxicity, treatment

Ovarian cancer is prone than Caucasian Europe and the United States, but recently the Taiwan people with the risk of ovarian cancer is also gradually increasing its greatest danger is early diagnosis difficult, in addition to using ultrasound, CT, even tumor marker CA-125 is very difficult to predict from, although tumor marker right up inspection Broken disease not help, but CA-125 in assessing treatment efficacy rather than tomography or ultrasound also accurate.
This is in Copenhagen, Denmark Gronlund's research team recently proposed to the report, 68 of ovarian cancer patients, topotecan plus carboplatin or paclitaxel in ovarian cancer with chemotherapy on the second line, tomography, ultrasound, or serum CA-125 concentration to assess the efficacy of chemotherapy results found that CA-125 concentrations than expensive tomography or complex sonography in predicting survival, 2.6 times more accuracy.

Tags: abdominal, age, blood, cancer, carboplatin, cause, chemotherapy, diagnosis, early, eat, gene, method, ovarian, paclitaxel, patients, prognosis, rate, risk, second, survival, tea, therapy, time, treatment, tumor

Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplatin and paclitaxel chemotherapy in a meeting, can significantly prolong survival, and patients can be tolerated. (Int J Cancer YORK 2005,15:45)

The case control study included surgery and platinum-based adjuvant chemotherapy complete remission for at least 6 months after the recurrence of ovarian cancer patients. Of the 68 patients, 27 patients received a weekly meeting of Taxol and carboplatin chemotherapy (WTJ) (Group I), carboplatin (AUC area under the curve for 2) plus paclitaxel (80 mg/m2); The remaining 41 patients (Group II) to platinum-based (P ) other chemotherapy, 37 patients with CAP program, a monthly meeting of carboplatin and paclitaxel program four cases.

Tags: cancer, carboplatin, cases, chemotherapy, clinical, drug, drugs, eat, family, gene, group, growth, increased, intraperitoneal, method, ovarian, ovary, p53, paclitaxel, patients, preventive, prognosis, protein, rate, risk, screening, second, study, surgery, survival, syndrome, taxol, therapy, time, treatment, women

Surgery

According to a medical examination and transvaginal ultrasound findings suspected ovarian cancer is often a laparotomy to be confirmed histology, and tumor stage and tumor debulking surgery. Histological need to be certified to remove ovarian cysts Mixed other causes, including non - epithelial ovarian cancer (such as interstitial or germ cell tumors), other primary site of tumor metastasis to the ovary (such as the adhesion of), or benign lesions, such as endometriosis. The adhesion is usually of signet ring cell tumor, representatives from primary adenocarcinoma of the stomach metastatic ovarian cancer. However, other parts of the original cancer, such as colon, appendix, the gallbladder and breast (special lobular invasive carcinoma) will also transfer to ovarian. At laparotomy surgery during the stage, right after the decision-making guidance provided important information, especially for patients with early (discussed below). Finally, the tumor debulking surgery (initial cytoreductive surgery) is the first of an important part of the operation because of residual tumor with a diameter of less than 1 cm larger than the residual tumor with a high survival rate.

Tags: abdominal, age, benign, bleeding, body, breast, cancer, carboplatin, carcinoma, care, cases, cause, cell, chemotherapy, cisplatin, clinical, cyst, cysts, diagnosis, drug, drugs, early, eat, ert, examination, exploration, gene, group, increased, intravenous, life, lymph, metastasis, metastatic, method, node, ovarian, ovary, paclitaxel, patients, pelvic, physical, poor, prognosis, quality, radiation, radiotherapy, rate, reduce, resection, residual, risk, screening, second, skin, staging, surface, surgery, surgical, survival, symptoms, syndrome, taxol, tea, therapy, time, treatment, tumor, tumors, usually, uterine

Although ovarian cancer chemotherapy drug developed considerable progress has been made, but patients with ovarian cancer and the overall survival rate has not improved markedly. Philadelphia's Fox Chase Hospital Dr. Bernard of ovarian cancer screening, treatment and prevention of, and possible future trends.

Tags: age, cancer, carboplatin, carcinoma, cause, cell, cells, chemotherapy, clinical, cox, drug, drugs, early, eat, exploration, grams, growth, incidence, method, ovarian, paclitaxel, patients, positive, preventive, protein, rate, reduce, response, risk, screening, surgical, survival, taxol, therapy, treatment, tumor

According to an obstetrics and gynecology oncology groups (GOG) study said that the smaller Phase III epithelial ovarian cancer patients, carboplatin and Taxol toxicity smaller, easier to use, the effect is less than cisplatin plus paclitaxel.

The non-randomized study data show that in advanced epithelial ovarian cancer, carboplatin and paclitaxel very effective, but less than the toxicity of cisplatin-based drugs, but its smaller, have unresectable Stage III cancer effects remain unknown. To this end, Philadelphia Fox Kaiser Cancer Center Aozhuoershi (Robert F. Ozols), and colleagues conducted a test to detect carboplatin and paclitaxel combined with cisplatin is secondary. 792 patients participated in this study, 400 were randomly assigned cisplatin (75 mg/m2) and paclitaxel (135 mg/m2) 24-hour infusion (group I), 392 with carboplatin (area under the curve of 7.5) and paclitaxel (175 mg / m2) 3-hour infusion (Group II). The two groups were 85% and 87% of the patients completed six cycles of treatment.

Tags: age, blood, cancer, carboplatin, cell, cisplatin, clinical, drug, drugs, eat, ert, group, groups, gynecological, infusion, ovarian, paclitaxel, patients, rate, second, study, survival, taxol, time, toxicity, treatment

Whitney physicians that cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer treatment should become the new standard.

Carboplatin / taxol treatment programs, and the current phase III epithelial ovarian tumors standard chemotherapy - cisplatin / paclitaxel, the same as its efficacy, toxicity small. Experts believe that the program should become a new standard treatment programs.

Combination of paclitaxel and cisplatin, paclitaxel must be sustained 24-hour infusion, and Taxol and carboplatin compatibility, 3-hour infusion of paclitaxel can, thus reducing low toxic side effects to a large extent.

Tags: age, cancer, carboplatin, cases, cause, chemotherapy, cisplatin, clinical, drug, early, eat, ert, exploration, grams, group, infusion, injection, method, ovarian, paclitaxel, pain, patients, prognosis, rate, residual, risk, second, study, surgery, survival, taxol, therapy, toxicity, treatment, tumor, tumors